| Literature DB >> 34208093 |
Claudie Lamoureux1,2, Charles-Antoine Guilloux1, Elise Courteboeuf1, Stéphanie Gouriou1, Clémence Beauruelle1,2, Geneviève Héry-Arnaud1,2,3.
Abstract
The importance and abundance of strict anaerobic bacteria in the respiratory microbiota of people with cystic fibrosis (PWCF) is now established through studies based on high-throughput sequencing or extended-culture methods. In CF respiratory niche, one of the most prevalent anaerobic genera is Prevotella, and particularly the species Prevotella melaninogenica. The objective of this study was to evaluate the antibiotic susceptibility of this anaerobic species. Fifty isolates of P. melaninogenica cultured from sputum of 50 PWCF have been included. Antibiotic susceptibility testing was performed using the agar diffusion method. All isolates were susceptible to the following antibiotics: amoxicillin/clavulanic acid, piperacillin/tazobactam, imipenem and metronidazole. A total of 96% of the isolates (48/50) were resistant to amoxicillin (indicating beta-lactamase production), 34% to clindamycin (17/50) and 24% to moxifloxacin (12/50). Moreover, 10% (5/50) were multidrug-resistant. A significant and positive correlation was found between clindamycin resistance and chronic azithromycin administration. This preliminary study on a predominant species of the lung "anaerobiome" shows high percentages of resistance, potentially exacerbated by the initiation of long-term antibiotic therapy in PWCF. The anaerobic resistome characterization, focusing on species rather than genera, is needed in the future to better prevent the emergence of resistance within lung microbiota.Entities:
Keywords: Prevotella melaninogenica; antibiotics susceptibility; cystic fibrosis; resistance
Year: 2021 PMID: 34208093 PMCID: PMC8230849 DOI: 10.3390/microorganisms9061275
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Study cohort characteristics: demographic, clinical and biological data. A total of 50 people with cystic fibrosis (PWCF) were included.
| PWCF Characteristics | Percentage ( | |
|---|---|---|
| Age group (years) | ≤6 | 4 (2) |
| 7–13 | 8 (4) | |
| 14–18 | 6 (3) | |
| 19–25 | 28 (14) | |
| 26–30 | 22 (11) | |
| ≥30 | 32 (16) | |
| Sex | Female | 48 (24) |
| Male | 52 (26) | |
| p.F508del mutation | Homozygote | 60 (30) |
| Heterozygote | 28 (14) | |
| Other mutations | 12 (6) | |
| Lung function (FEV1 %) | ≤40 | 26 (13) |
| 40–70 | 52 (26) | |
| >70 | 22 (11) | |
| Chronic antibiotic | Azithromycin | 44 (22) |
| Aztreonam | 10 (5) | |
| Colistin | 42 (21) | |
| Tobramycin | 20 (10) | |
| Antibiotics administration one month before the sample | Oral * | 36 (18) |
| Intravenous ** | 16 (8) | |
* amoxicillin/clavulanic acid, cefpodoxime, ciprofloxacin, doxycycline, linezolid, minocycline, pristinamycin, trimetoprim/sulfamethoxazole, ** amikacin, aztreonam, ceftazidime, doxycycline, linezolid, meropenem, piperacillin/tazobactam, tobramycin, trimetoprim/sulfamethoxazole, FEV1: Forced Expiratory Volume in one second.
Antibiotic susceptibilities of 50 isolates of Prevotella melaninogenica (according to recommendations of EUCAST/CASFM 2019 [21].
| Antibiotic | Interpretative Categories n (%) | |
|---|---|---|
| S | R | |
| Amoxicillin | 2 (4) | 48 (96) |
| Amoxicillin/clavulanic acid | 50 (100) | 0 |
| Piperacillin/tazobactam | 50 (100) | 0 |
| Imipenem | 50 (100) | 0 |
| Clindamycin | 33 (66) | 17 (34) |
| Moxifloxacin | 38 (76) | 12 (24) |
| Metronidazole | 50 (100) | 0 |
S: susceptible, R: resistant.
Figure 1Distribution of minimum inhibitory concentration (MIC) for amoxicillin (mg/L) among the 50 isolates of Prevotella melaninogenica.
Studies reporting the percentage of beta-lactamase activity in Prevotella spp.
| Beta-Lactamase Activity (%) | Number of Isolates | Cystic Fibrosis | Method of Detection | ||
|---|---|---|---|---|---|
| This study | 96 | 50 |
| Yes | MIC of amoxicillin |
| Bahar et al., 2005 [ | 68 | 19 |
| No | Nitrocefin test |
| Fujita et al., 2019 [ | 85 | 27 | 5 | No | Nitrocefin test |
| Bancescu et al., 2015 [ | 33 | 33 | 5 | No | Nitrocefin test |
| Fernandez et al., 2015 [ | 46 | 41 | 2 | No | Nitrocefin test |
| Montagner et al., 2014 [ | 20 | 15 | 4 | No | Nitrocefin test |
| Sherrard et al., 2013 [ | 59 | 157 | Yes and no | Nitrocefin test | |
| Tran et al., 2013 [ | 75 | 16 | No | Nitrocefin test | |
| Kuriyama et al., 2007 [ | 37 | 499 | No | Nitrocefin test | |
| Mosca et al., 2007 [ | 18 | 39 | 3 | No | Nitrocefin test |
| Iwahara et al., 2006 [ | 31 | 139 | 8 | No | Nitrocefin test |
| Behra-Miellet et al., 2003 [ | 65 | 40 | No | Nitrocefin test | |
| Dubreuil et al., 2003 [ | 58 | 100 | 12 | No | Nitrocefin test |
| Matto et al., 1999 [ | 31 | 171 | 3 | No | Nitrocefin test |
Studies reporting antibiotic resistance of Prevotella spp.
| Reference | Cystic Fibrosis | Isolates Identification | Number of Isolates | Location | Percentage of Resistance | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amoxicillin or Ampicillin | Amoxicillin/Clavulanic Acid | Piperacillin/Tazobactam | Imipenem | Clindamycine | Moxifloxacine | Metronidazole | ||||||
| This study | Yes |
| Mass spectrometry | 50 | France | 96.0 | 0 | 0 | 0 | 34.0 | 24.0 | 0 |
| Veloo et al., 2019 [ | No |
| Mass spectrometry | 21 | Netherlands | 66.7 | - | - | - | 4.8 | - | 4.8 |
| Ulger Toprak et al., 2018 [ | No |
| 16S rRNA gene sequencing | 44 | 11 countries | 67.4 | - | - | - | 16.3 | 20.5 | - |
| Bahar et al., 2005 [ | No |
| Biochemical tests | 19 | Turkey | - | - | - | 0 | 10.5 | - | 0 |
| Byun et al., 2019 [ | No | 8 | Mass spectrometry | 33 | Korea | - | - | 0 | 0 | 45.0 | 9.0 | 3.0 |
| Cobo et al., 2019 [ | No | Mass spectrometry | 30 | Spain | - | 0 | 3.0 | 0 | 40.0 | 30.0 | 7.0 | |
| Bancescu et al., 2015 [ | No | Biochemical tests | 33 | Romania | 33.0 | 0 | - | - | 3.0 | - | 0 | |
| Shilnikova et al., 2014 [ | No | 13 | Mass spectrometry | 42 | Russia | - | 0 | - | 0 | 11.9 | - | 4.8 |
| Xie et al., 2014 [ | No | 10 | 16S rRNA gene sequencing | 42 | China | 30.9 | - | - | 0 | 38.1 | - | 9.5 |
| Tran et al., 2013 [ | No | 16S rRNA gene sequencing | 16 | Japon | 69.0 | - | 0 | 0 | 19.0 | - | 0 | |
| Seifert et al., 2010 [ | No | 7 | Biochemical tests | 21 | Germany | - | - | - | - | 9.5 | 0 | 0 |
| Papaparaskevas et al., 2008 [ | No | 10 | Biochemical tests | 141 | Greece | - | - | 0 | 0 | 31.0 | 38.0 | 8.0 |
| Tunney et al., | Yes | 4 | Biochemical tests | 14 | Ireland | 36.0 | - | 7.0 | - | 36.0 | - | 46.0 |
| Mosca et al., 2007 [ | No | 3 | Biochemical tests | 39 | Italy | 18.0 | 0 | - | - | - | 7.7 | 0 |
| Behra-Miellet et al., 2003 [ | No | Biochemical tests | 40 | France | 65.0 | 0 | - | 0 | 5.0 | - | 0 | |
| Mory et al., 1998 [ | No | 10 | Biochemical tests | 56 | France | 25.0 | 0 | - | 0 | 0 | - | 0 |